Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results